Petition for PBS Fampyra
January 29, 2014
Carer Brenda Fisher has
collected more than 10,000
signatures supporting Fampyra
(fampridine) to be included on the
Pharmaceutical Benefits Scheme.
Fampyra is a treatment for
mobility impairment for people
with Multiple Sclerosis (MS)
and will be considered by the
Pharmaceutical Benefits Advisory
Committee (PBAC) in March.
Fisher, whose husband was
diagnosed with MS, will present the
petition today to Victorian Senator
Scott Ryan, who has offered to
table the petition, started a year
ago, in Federal Parliament.
MS Australia ceo Debra Cerasa
said there was clear evidence
linking mobility among MS patients
and quality of life.
Cerasa said MS Australia
supported the inclusion of more
treatments on the PBS.
“The fact is, MS is a complex
disease.
“No two cases are ever the same
and that’s why people with MS
need subsidised treatments, so
they have choice and flexibility to
find the treatment option that is
right for them.”
The PBAC rejected the Fampyra
submission for subsidisation in
Nov 2012 on the basis of unclear
evidence of clinical benefit and
that the economic analysis did not
provide sufficient basis to conclude
that treatment with fampridine was
cost-effective.
To read more, CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jan 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jan 14
